FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387165200> ?p ?o ?g. }

• W4387165200 endingPage "e34562" @default.
• W4387165200 startingPage "e34562" @default.
• W4387165200 abstract "Elevated blood levels of low-density lipoprotein cholesterol are a major cardiovascular risk factor, and cholesterol-lowering drugs are among the most prescribed drugs worldwide. Cancer is the second leading cause of death after cardiovascular diseases. The relationship between cancer development and statins intake is controversial, and there are no clear studies in Lebanon and the Middle East concerning this topic. Hence, our study aimed to search for any possible association of statin intake as well as other medications (proton pump inhibitors [PPI], metformin, Aspirin, Angiotensin-Converting Enzyme inhibitors, and fenofibrate) with lung, colorectal cancer (CRC), and bladder cancer development in the Lebanese population. A retrospective study was performed on 709 subjects divided into 2 main groups: control (no cancer ± statin intake), and cases (either lung, or colorectal, or bladder cancer ± statin intake). Collected data included the age and gender of the patient, socioeconomic status, presence of cardiovascular disease and comorbidities, cancer risk factors, and the intake type, dose, and duration of statins. Bivariate, multivariate, and binary logistic analyses were enrolled. Out of 709 participants, 63.2% were males and 75% were cancer-positive (24.1%: lung cancer, 26.7%: CRC, 24.1%: bladder cancer). The overall intake of statins was not shown to significantly affect cancer development. However, a duration-response relationship was established between Simvastatin and lung cancer (odds ratio [OR]=1.208) as well as bladder cancer (OR=1.189). No significant association was found between each statin and CRC. Although PPIs intake was associated with a possibly harmful effect on lung cancer development (OR=3.42), it revealed a protective association with CRC development (OR=0.38). Other risk factors such as smoking and age were strongly associated (harmful) with lung and bladder cancer development. Physical inactivity and a family history of CRC were each associated with a harmful effect on CRC development. A harmful association with the development of lung and bladder cancer was found with the increasing duration of intake of Simvastatin. Other drugs such as PPIs and specific risk factors were also associated negatively or positively with the development of these 3 cancers. These findings should be validated by further investigations to guide clinicians on optimal treatment options for their patients." @default.
• W4387165200 created "2023-09-30" @default.
• W4387165200 creator A5000683931 @default.
• W4387165200 creator A5003622080 @default.
• W4387165200 creator A5022533223 @default.
• W4387165200 creator A5029250006 @default.
• W4387165200 creator A5031972843 @default.
• W4387165200 creator A5068500022 @default.
• W4387165200 creator A5092772851 @default.
• W4387165200 creator A5092772852 @default.
• W4387165200 creator A5092772853 @default.
• W4387165200 date "2023-09-29" @default.
• W4387165200 modified "2023-10-05" @default.
• W4387165200 title "Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study" @default.
• W4387165200 cites W1986186950 @default.
• W4387165200 cites W1992152105 @default.
• W4387165200 cites W2001644952 @default.
• W4387165200 cites W2021103317 @default.
• W4387165200 cites W2042944093 @default.
• W4387165200 cites W2043263931 @default.
• W4387165200 cites W2074143992 @default.
• W4387165200 cites W2076864596 @default.
• W4387165200 cites W2091624467 @default.
• W4387165200 cites W2137405846 @default.
• W4387165200 cites W2137983259 @default.
• W4387165200 cites W2285495710 @default.
• W4387165200 cites W2290005970 @default.
• W4387165200 cites W2318626491 @default.
• W4387165200 cites W2346529877 @default.
• W4387165200 cites W2508820273 @default.
• W4387165200 cites W2534069516 @default.
• W4387165200 cites W2609812301 @default.
• W4387165200 cites W2614986146 @default.
• W4387165200 cites W2698787955 @default.
• W4387165200 cites W2884549606 @default.
• W4387165200 cites W2900034165 @default.
• W4387165200 cites W3024546847 @default.
• W4387165200 cites W3032761626 @default.
• W4387165200 cites W3105175575 @default.
• W4387165200 cites W3117196393 @default.
• W4387165200 cites W3128646645 @default.
• W4387165200 cites W3181922658 @default.
• W4387165200 cites W3188611133 @default.
• W4387165200 doi "https://doi.org/10.1097/md.0000000000034562" @default.
• W4387165200 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37773843" @default.
• W4387165200 hasPublicationYear "2023" @default.
• W4387165200 type Work @default.
• W4387165200 citedByCount "0" @default.
• W4387165200 crossrefType "journal-article" @default.
• W4387165200 hasAuthorship W4387165200A5000683931 @default.
• W4387165200 hasAuthorship W4387165200A5003622080 @default.
• W4387165200 hasAuthorship W4387165200A5022533223 @default.
• W4387165200 hasAuthorship W4387165200A5029250006 @default.
• W4387165200 hasAuthorship W4387165200A5031972843 @default.
• W4387165200 hasAuthorship W4387165200A5068500022 @default.
• W4387165200 hasAuthorship W4387165200A5092772851 @default.
• W4387165200 hasAuthorship W4387165200A5092772852 @default.
• W4387165200 hasAuthorship W4387165200A5092772853 @default.
• W4387165200 hasBestOaLocation W43871652001 @default.
• W4387165200 hasConcept C121608353 @default.
• W4387165200 hasConcept C126322002 @default.
• W4387165200 hasConcept C143998085 @default.
• W4387165200 hasConcept C156957248 @default.
• W4387165200 hasConcept C2776256026 @default.
• W4387165200 hasConcept C2776839432 @default.
• W4387165200 hasConcept C2777628954 @default.
• W4387165200 hasConcept C2780352672 @default.
• W4387165200 hasConcept C2908647359 @default.
• W4387165200 hasConcept C526805850 @default.
• W4387165200 hasConcept C71924100 @default.
• W4387165200 hasConcept C99454951 @default.
• W4387165200 hasConceptScore W4387165200C121608353 @default.
• W4387165200 hasConceptScore W4387165200C126322002 @default.
• W4387165200 hasConceptScore W4387165200C143998085 @default.
• W4387165200 hasConceptScore W4387165200C156957248 @default.
• W4387165200 hasConceptScore W4387165200C2776256026 @default.
• W4387165200 hasConceptScore W4387165200C2776839432 @default.
• W4387165200 hasConceptScore W4387165200C2777628954 @default.
• W4387165200 hasConceptScore W4387165200C2780352672 @default.
• W4387165200 hasConceptScore W4387165200C2908647359 @default.
• W4387165200 hasConceptScore W4387165200C526805850 @default.
• W4387165200 hasConceptScore W4387165200C71924100 @default.
• W4387165200 hasConceptScore W4387165200C99454951 @default.
• W4387165200 hasIssue "39" @default.
• W4387165200 hasLocation W43871652001 @default.
• W4387165200 hasLocation W43871652002 @default.
• W4387165200 hasOpenAccess W4387165200 @default.
• W4387165200 hasPrimaryLocation W43871652001 @default.
• W4387165200 hasRelatedWork W1959574449 @default.
• W4387165200 hasRelatedWork W2019059391 @default.
• W4387165200 hasRelatedWork W2064286441 @default.
• W4387165200 hasRelatedWork W2332797319 @default.
• W4387165200 hasRelatedWork W2367823310 @default.
• W4387165200 hasRelatedWork W2542248393 @default.
• W4387165200 hasRelatedWork W2777287390 @default.
• W4387165200 hasRelatedWork W2950169628 @default.
• W4387165200 hasRelatedWork W2978156863 @default.
• W4387165200 hasRelatedWork W2981851942 @default.

• next